AMED ecosystem programme support · Biotech

Surv BioPharma selected for up to ¥2.7 billion in AMED support

The programme backs development of the company’s immune-gene oncolytic virus.

AMED selected Surv BioPharma’s Surv.m-CRA-2-IC programme for its Drug Discovery Venture Ecosystem initiative on 4 December 2025. In a 22 December announcement, the company put the potential support at up to approximately ¥2.7 billion over the project’s full term.

The subsidy is linked to investment by certified venture capital firms. Those firms must provide at least one-third of eligible research and development costs; AMED can provide up to twice their investment. DCI Partners is the project’s lead certified VC.

Surv BioPharma plans to advance nonclinical and clinical development of its immune-gene oncolytic virus for difficult-to-treat cancers.

Use of funds

Nonclinical and clinical development of Surv.m-CRA-2-IC

Funding history

AMED ecosystem programme support · This round≤¥2.7B
Series B first close¥1.5B

Sources

  1. amed.go.jp
  2. Surv BioPharma announces up toJPY2.7bn AMED ecosystem supportsurvbiopharma.co.jp · Dec 22, 2025